Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in Pharma Business Management and Research : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen
| Advances in Pharma Business Management and Research : Volume 1 / / edited by Lars Schweizer, Theodor Dingermann, Otto Quintus Russe, Christian Jansen |
| Autore | Schweizer Lars |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Springer Nature, 2020 |
| Descrizione fisica | 1 online resource (X, 85 p. 11 illus.) |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical technology
Health care management Health services administration Medical laws and legislation Pharmacy Pharmacy management Pharmaceutical Sciences/Technology Health Care Management Medical Law Pharmacoeconomics and Health Outcomes |
| Soggetto non controllato |
Pharmaceutical Sciences/Technology
Health Care Management Medical Law Pharmacy Pharmacoeconomics and Health Outcomes Pharmaceutics Health Care Pharmacology Pharma Management Market Access Regulatory Affairs Research & Development Quality Control Open Access Industrial chemistry & chemical engineering Health economics Medical & healthcare law Pharmacy / dispensing |
| ISBN | 3-030-35918-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry -- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context -- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company -- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies -- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi -- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management. |
| Record Nr. | UNINA-9910380742003321 |
Schweizer Lars
|
||
| Springer Nature, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular biology in medicinal chemistry [[electronic resource] /] / edited by Th. Dingermann, D. Steinhilber and G. Folkers
| Molecular biology in medicinal chemistry [[electronic resource] /] / edited by Th. Dingermann, D. Steinhilber and G. Folkers |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2004 |
| Descrizione fisica | 1 online resource (437 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
DingermannTheodor
FolkersGerd SteinhilberDieter <1959-> |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Chiral drugs
Genomics Molecular biology Molecular pharmacology Pharmacogenomics |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-52027-2
9786610520275 3-527-60518-5 3-527-60266-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular Biology in Medicinal Chemistry; Contents; Preface; Foreword; Contributors; Part I Molecular Targets; 1 Cellular Assays in Drug Discovery; 1.1 Introduction; 1.1.1 Positioning Cellular Assays; 1.1.2 Impact on Drug Discovery; 1.1.3 Classification of Cellular Assays; 1.1.4 Progress in Tools and Technologies for Cellular Compound Profiling; 1.2 Membrane Proteins and Fast Cellular Responses; 1.2.1 Receptors; 1.2.1.1 FLIPR Technology for Detection of Intracellular Calcium Release; 1.2.1.2 Competitive Immunoassay for Detection of Intracellular cAMP
1.2.1.3 Enzyme Fragment Complementation (EFC) Technology1.2.2 Membrane Transport Proteins; 1.2.2.1 Ion Channels; 1.2.2.2 MDR Proteins; 1.3 Gene and Protein Expression Profiling in High-throughput Formats; 1.3.1 Reporter Gene Assays in Lead Finding; 1.3.2 Reporter Gene Assays in Lead Optimization; 1.4 Spatio-temporal Assays and Subpopulation Analysis; 1.4.1 Phosphorylation Stage-specific Antibodies; 1.4.2 Target-protein-specific Antibodies; 1.4.3 Protein-GFP Fusions; 1.4.4 Fluorescence Resonance Energy Transfer (FRET) 1.4.5 GPCR Activation using Bioluminescence Resonance Energy Transfer (BRET)1.4.6 Protein Fragment Complementation Assays (PCA); 1.5 Phenotypic Assays; 1.5.1 Proliferation/Respiration/Toxicity; 1.5.2 Apoptosis; 1.5.3 Differentiation; 1.5.4 Monitoring Cell Metabolism; 1.5.5 Other Phenotypic Assays; Acknowledgments; References; 2 Gene Knockout Models; 2.1 Introduction; 2.2 Gene Knockout Mice; 2.2.1 ES Cells; 2.2.2 Targeting Vector; 2.2.3 Selection of Recombinant ES Cells; 2.2.4 Injection of Recombinant ES Cells into Blastocysts and Blastocyst Transfer to Pseudopregnant Recipients 2.2.5 Chimeras and F1 and F2 Offspring2.3 Tissue-Specific Gene Expression; 2.3.1 Ligand-Activated CRE Recombinases; 2.3.2 The Tetracycline/Doxycycline-Inducible Expression System; 2.4 Transgenic Mice; 2.5 Targeted Gene Disruption in Drosophila; 2.6 Targeted Gene Knockdown in Zebrafish; 2.7 Targeted Caenorhabditis Elegans Deletion Strains; References; 3 Reporter Gene Assay Systems for the Investigation of G-protein-coupled Receptors; 3.1 Receptors and Cellular Communication; 3.1.1 Ion Channel-linked Receptors; 3.1.2 Enzyme-linked Cell-surface Receptors; 3.1.3 GPCRs 3.2 Affinity and Activity of GPCR Ligands3.3 The Role of Transcription Factors in Gene Expression; 3.3.1 CREB; 3.3.2 SRF; 3.3.3 STAT Proteins; 3.3.4 c-Jun; 3.3.5 NF-AT; 3.4 Reporter Genes; 3.4.1 CAT; 3.4.2 β-Gal; 3.4.3 β-Glucuronidase; 3.4.4 AP; 3.4.5 SEAP; 3.4.6 β-Lactamase; 3.4.7 Luciferase; 3.4.8 GFP; 3.5 Reporter Gene Assay Systems for the Investigation of GPCRs; 3.5.1 Application of Luciferase as a Reporter Gene; 3.5.2 Application of other Reporter Genes for the Investigation of GPCRs; References; 4 From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors 4.1 Introduction |
| Record Nr. | UNINA-9910146243903321 |
| Weinheim, : Wiley-VCH, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular biology in medicinal chemistry [[electronic resource] /] / edited by Th. Dingermann, D. Steinhilber and G. Folkers
| Molecular biology in medicinal chemistry [[electronic resource] /] / edited by Th. Dingermann, D. Steinhilber and G. Folkers |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2004 |
| Descrizione fisica | 1 online resource (437 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
DingermannTheodor
FolkersGerd SteinhilberDieter <1959-> |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Chiral drugs
Genomics Molecular biology Molecular pharmacology Pharmacogenomics |
| ISBN |
1-280-52027-2
9786610520275 3-527-60518-5 3-527-60266-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular Biology in Medicinal Chemistry; Contents; Preface; Foreword; Contributors; Part I Molecular Targets; 1 Cellular Assays in Drug Discovery; 1.1 Introduction; 1.1.1 Positioning Cellular Assays; 1.1.2 Impact on Drug Discovery; 1.1.3 Classification of Cellular Assays; 1.1.4 Progress in Tools and Technologies for Cellular Compound Profiling; 1.2 Membrane Proteins and Fast Cellular Responses; 1.2.1 Receptors; 1.2.1.1 FLIPR Technology for Detection of Intracellular Calcium Release; 1.2.1.2 Competitive Immunoassay for Detection of Intracellular cAMP
1.2.1.3 Enzyme Fragment Complementation (EFC) Technology1.2.2 Membrane Transport Proteins; 1.2.2.1 Ion Channels; 1.2.2.2 MDR Proteins; 1.3 Gene and Protein Expression Profiling in High-throughput Formats; 1.3.1 Reporter Gene Assays in Lead Finding; 1.3.2 Reporter Gene Assays in Lead Optimization; 1.4 Spatio-temporal Assays and Subpopulation Analysis; 1.4.1 Phosphorylation Stage-specific Antibodies; 1.4.2 Target-protein-specific Antibodies; 1.4.3 Protein-GFP Fusions; 1.4.4 Fluorescence Resonance Energy Transfer (FRET) 1.4.5 GPCR Activation using Bioluminescence Resonance Energy Transfer (BRET)1.4.6 Protein Fragment Complementation Assays (PCA); 1.5 Phenotypic Assays; 1.5.1 Proliferation/Respiration/Toxicity; 1.5.2 Apoptosis; 1.5.3 Differentiation; 1.5.4 Monitoring Cell Metabolism; 1.5.5 Other Phenotypic Assays; Acknowledgments; References; 2 Gene Knockout Models; 2.1 Introduction; 2.2 Gene Knockout Mice; 2.2.1 ES Cells; 2.2.2 Targeting Vector; 2.2.3 Selection of Recombinant ES Cells; 2.2.4 Injection of Recombinant ES Cells into Blastocysts and Blastocyst Transfer to Pseudopregnant Recipients 2.2.5 Chimeras and F1 and F2 Offspring2.3 Tissue-Specific Gene Expression; 2.3.1 Ligand-Activated CRE Recombinases; 2.3.2 The Tetracycline/Doxycycline-Inducible Expression System; 2.4 Transgenic Mice; 2.5 Targeted Gene Disruption in Drosophila; 2.6 Targeted Gene Knockdown in Zebrafish; 2.7 Targeted Caenorhabditis Elegans Deletion Strains; References; 3 Reporter Gene Assay Systems for the Investigation of G-protein-coupled Receptors; 3.1 Receptors and Cellular Communication; 3.1.1 Ion Channel-linked Receptors; 3.1.2 Enzyme-linked Cell-surface Receptors; 3.1.3 GPCRs 3.2 Affinity and Activity of GPCR Ligands3.3 The Role of Transcription Factors in Gene Expression; 3.3.1 CREB; 3.3.2 SRF; 3.3.3 STAT Proteins; 3.3.4 c-Jun; 3.3.5 NF-AT; 3.4 Reporter Genes; 3.4.1 CAT; 3.4.2 β-Gal; 3.4.3 β-Glucuronidase; 3.4.4 AP; 3.4.5 SEAP; 3.4.6 β-Lactamase; 3.4.7 Luciferase; 3.4.8 GFP; 3.5 Reporter Gene Assay Systems for the Investigation of GPCRs; 3.5.1 Application of Luciferase as a Reporter Gene; 3.5.2 Application of other Reporter Genes for the Investigation of GPCRs; References; 4 From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors 4.1 Introduction |
| Record Nr. | UNINA-9910830570303321 |
| Weinheim, : Wiley-VCH, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular biology in medicinal chemistry / / edited by Th. Dingermann, D. Steinhilber and G. Folkers
| Molecular biology in medicinal chemistry / / edited by Th. Dingermann, D. Steinhilber and G. Folkers |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, 2004 |
| Descrizione fisica | 1 online resource (437 p.) |
| Disciplina | 615.19 |
| Altri autori (Persone) |
DingermannTheodor
FolkersGerd SteinhilberDieter <1959-> |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Chiral drugs
Genomics Molecular biology Molecular pharmacology Pharmacogenomics |
| ISBN |
1-280-52027-2
9786610520275 3-527-60518-5 3-527-60266-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Molecular Biology in Medicinal Chemistry; Contents; Preface; Foreword; Contributors; Part I Molecular Targets; 1 Cellular Assays in Drug Discovery; 1.1 Introduction; 1.1.1 Positioning Cellular Assays; 1.1.2 Impact on Drug Discovery; 1.1.3 Classification of Cellular Assays; 1.1.4 Progress in Tools and Technologies for Cellular Compound Profiling; 1.2 Membrane Proteins and Fast Cellular Responses; 1.2.1 Receptors; 1.2.1.1 FLIPR Technology for Detection of Intracellular Calcium Release; 1.2.1.2 Competitive Immunoassay for Detection of Intracellular cAMP
1.2.1.3 Enzyme Fragment Complementation (EFC) Technology1.2.2 Membrane Transport Proteins; 1.2.2.1 Ion Channels; 1.2.2.2 MDR Proteins; 1.3 Gene and Protein Expression Profiling in High-throughput Formats; 1.3.1 Reporter Gene Assays in Lead Finding; 1.3.2 Reporter Gene Assays in Lead Optimization; 1.4 Spatio-temporal Assays and Subpopulation Analysis; 1.4.1 Phosphorylation Stage-specific Antibodies; 1.4.2 Target-protein-specific Antibodies; 1.4.3 Protein-GFP Fusions; 1.4.4 Fluorescence Resonance Energy Transfer (FRET) 1.4.5 GPCR Activation using Bioluminescence Resonance Energy Transfer (BRET)1.4.6 Protein Fragment Complementation Assays (PCA); 1.5 Phenotypic Assays; 1.5.1 Proliferation/Respiration/Toxicity; 1.5.2 Apoptosis; 1.5.3 Differentiation; 1.5.4 Monitoring Cell Metabolism; 1.5.5 Other Phenotypic Assays; Acknowledgments; References; 2 Gene Knockout Models; 2.1 Introduction; 2.2 Gene Knockout Mice; 2.2.1 ES Cells; 2.2.2 Targeting Vector; 2.2.3 Selection of Recombinant ES Cells; 2.2.4 Injection of Recombinant ES Cells into Blastocysts and Blastocyst Transfer to Pseudopregnant Recipients 2.2.5 Chimeras and F1 and F2 Offspring2.3 Tissue-Specific Gene Expression; 2.3.1 Ligand-Activated CRE Recombinases; 2.3.2 The Tetracycline/Doxycycline-Inducible Expression System; 2.4 Transgenic Mice; 2.5 Targeted Gene Disruption in Drosophila; 2.6 Targeted Gene Knockdown in Zebrafish; 2.7 Targeted Caenorhabditis Elegans Deletion Strains; References; 3 Reporter Gene Assay Systems for the Investigation of G-protein-coupled Receptors; 3.1 Receptors and Cellular Communication; 3.1.1 Ion Channel-linked Receptors; 3.1.2 Enzyme-linked Cell-surface Receptors; 3.1.3 GPCRs 3.2 Affinity and Activity of GPCR Ligands3.3 The Role of Transcription Factors in Gene Expression; 3.3.1 CREB; 3.3.2 SRF; 3.3.3 STAT Proteins; 3.3.4 c-Jun; 3.3.5 NF-AT; 3.4 Reporter Genes; 3.4.1 CAT; 3.4.2 β-Gal; 3.4.3 β-Glucuronidase; 3.4.4 AP; 3.4.5 SEAP; 3.4.6 β-Lactamase; 3.4.7 Luciferase; 3.4.8 GFP; 3.5 Reporter Gene Assay Systems for the Investigation of GPCRs; 3.5.1 Application of Luciferase as a Reporter Gene; 3.5.2 Application of other Reporter Genes for the Investigation of GPCRs; References; 4 From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors 4.1 Introduction |
| Record Nr. | UNINA-9910877222403321 |
| Weinheim, : Wiley-VCH, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||